AGCO: Shorts Pare Back as Street Splits on the Recovery

AGCO has spent the past week in an odd position: the stock added 7.5% after last week's earnings beat, shorts have quietly started trimming, and the analyst community cannot agree on whether the cycle is turning.

The short position has started to unwind, though only modestly. Short interest edged down to 5.1% of free float from 5.2% a week ago, the first meaningful reversal after a sharp 26% build over the past month. That prior accumulation was the dominant story in last week's note; the new data point is that it has stopped growing. Cost to borrow remains negligible at 0.46%, and availability has actually tightened relative to the week prior, dropping from roughly 466% to 430%, though that still represents more than four shares available to borrow for every one already shorted. There is no squeeze pressure in the lending market. The ORTEX short score has crept up to 49.6 from 46.6 two weeks ago, sitting squarely at the neutral midpoint. The picture is one of a short base that built aggressively into the print, took the 8.6% day-after surge without covering in size, and is now gently reducing rather than pressing further.

Options positioning reinforces the cautiously constructive tone. The put/call ratio has dipped to 0.19, below its 20-day average of 0.18, and well off the 52-week high of 1.52. That means call volume is running heavily above put volume, the opposite of a defensive setup. The z-score of 0.83 is not extreme, but the direction of travel from early October, when PCR was running closer to 0.15 to 0.16, is a mild rotation into more balanced hedging rather than aggressive downside protection. Taken together, options and short positioning describe a market that is cautious but not panicked.

The Street is the more interesting battleground. Morgan Stanley maintained its Underweight rating on November 4 but raised its target to $113 from $99, a tacit acknowledgment that the earnings print was better than feared without flipping the thesis. That target sits barely above the current price of $111.17. JP Morgan's Overweight with a $145 target from last week stands at the other end, implying 30% upside. Truist, still at Buy, trimmed to $136 from $146 on November 2. Barclays sits at Underweight with a $97 target. The mean price target across the panel is $124.93, about 12% above where the stock is trading, but the dispersion is unusually wide. The bull case rests on the European franchise generating a disproportionate share of operating income, early momentum in the PTx precision agriculture technology ecosystem, and a potential North American cyclical turn from a very low base. The bear case is harder to dismiss: North American heavy tractor retail sales have fallen year-over-year for 25 consecutive months, and Latin American revenues dropped 30% in the first quarter. Neither side looks obviously wrong.

One structural feature worth noting is the ownership register. A Schedule 13D activist position, filed by Srinivasan Mallika, declares 16.3% of the company, unchanged from the previous filing. That is a significant concentrated stake with an explicitly activist character. As always with 13D/G disclosures, the position is as of the last filing date, and holders who fall below the 5% threshold may exit without further notice. T. Rowe Price's passive 13G stake, which previously ran at 8.7% of shares, was last disclosed at 6.8% as of August 2025. Among institutional holders, Invesco added 555,000 shares in the most recently reported quarter, the largest incremental buyer in the top-15 list by a wide margin. Net insider activity over the 90 days to mid-September was a net sale of roughly 499,000 shares worth $57.6 million, though the dominant transaction was a large disposal by Tractors & Farm Equipment Ltd, a 10% owner, rather than C-suite discretionary selling.

AGCO's next earnings event is not until February 5, 2027, leaving 93 days for the demand cycle thesis to either gather evidence or erode further. The question heading into that print is whether the North American dealer destocking story, which dominated the bear case through 2025 and into 2026, begins to show any sign of a floor, and whether PTx Trimble volumes recover enough to support management's mid-cycle margin targets.